Clinical Trial Update: Study of Combination PS-341 and Thalidomide in Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial assessing the combination of PS-341 (bortezomib) and thalidomide in patients with multiple myeloma; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• PS-341 (bortezomib) (bortezomib)
• Thalidomide (thalidomide)

Snippet

Sponsor: University of Arkansas | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED